230 related articles for article (PubMed ID: 27184548)
1. Personalized prostate cancer care: from screening to treatment.
Conran CA; Brendler CB; Xu J
Asian J Androl; 2016; 18(4):505-8. PubMed ID: 27184548
[TBL] [Abstract][Full Text] [Related]
2. Essential elements of personalized medicine.
Burke W; Brown Trinidad S; Press NA
Urol Oncol; 2014 Feb; 32(2):193-7. PubMed ID: 24321254
[TBL] [Abstract][Full Text] [Related]
3. Genomics to personalize care of prostate cancer.
Connors LM
J Am Assoc Nurse Pract; 2020 Feb; 32(2):106-108. PubMed ID: 32015276
[TBL] [Abstract][Full Text] [Related]
4. [Prostate cancer in the era of precision medicine: a new horizon].
Nguyen-Ngoc T; Berthold D; Normand C
Rev Med Suisse; 2023 May; 19(827):950-956. PubMed ID: 37195108
[TBL] [Abstract][Full Text] [Related]
5. Prognostic outlier genes for enhanced prostate cancer treatment.
Kim H; Skowronski J; Den RB
Future Oncol; 2017 Feb; 13(3):249-261. PubMed ID: 27728977
[TBL] [Abstract][Full Text] [Related]
6. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
7. Omics sciences and precision medicine in prostate cancer.
Medori MC; Micheletti C; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Bernini A; Fulcheri E; Calogero AE; Cannarella R; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):95-103. PubMed ID: 37994753
[TBL] [Abstract][Full Text] [Related]
8. Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine.
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2016 Oct; 12(20):2359-61. PubMed ID: 27424848
[No Abstract] [Full Text] [Related]
9. Precision medicine for prostate cancer.
Galazi M; Rodriguez-Vida A; Ng T; Mason M; Chowdhury S
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1305-15. PubMed ID: 25354871
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
[TBL] [Abstract][Full Text] [Related]
11. [Precision Health in Nursing Practice].
Lin WL; Wang HH; Chen KM
Hu Li Za Zhi; 2023 Feb; 70(1):96-100. PubMed ID: 36647315
[TBL] [Abstract][Full Text] [Related]
12. The socioeconomic implications of prostate-specific antigen screening.
Benoit RM; Naslund MJ
Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
[TBL] [Abstract][Full Text] [Related]
13. [Using the theory of precision medicine to optimize the multidisciplinary comprehensive treatment of prostate cancer].
Ye DW; Zhu Y
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):401-403. PubMed ID: 31142061
[TBL] [Abstract][Full Text] [Related]
14. Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology.
Mertan F; Turkbey B
Pharmacol Res; 2016 Dec; 114():163-165. PubMed ID: 27777131
[TBL] [Abstract][Full Text] [Related]
15. [Personalized medicine and prostate cancer. The reality of change].
Carballido Rodríguez JA; Martínez-Salamanca JI
Arch Esp Urol; 2015 Apr; 68(3):391-400. PubMed ID: 25948808
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
[TBL] [Abstract][Full Text] [Related]
17. Personalized strategies in population screening for prostate cancer.
Remmers S; Roobol MJ
Int J Cancer; 2020 Dec; 147(11):2977-2987. PubMed ID: 32394421
[TBL] [Abstract][Full Text] [Related]
18. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease.
Strianese O; Rizzo F; Ciccarelli M; Galasso G; D'Agostino Y; Salvati A; Del Giudice C; Tesorio P; Rusciano MR
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
